Our Goals

BiOrigin aims to support the establishment and management of early-stage life science companies, primarily within the Novo Seeds portfolio.

BiOrigin provides different types of strategic and operational support to companies and projects in order to help them steer through the critical start-up and subsequent growth phase.

BiOrigin is the “Entrepreneur-in-Residence” team for Novo Seeds

What we do


We help clients advance new therapies by designing R&D plans and providing management services to support projects across the spectrum of development


We support the fund-raising process by devising strategies to access a broad network of private and venture capital, as well as supporting efforts for soft sources of funding. Once financed, we also offer financial management services from accounting, budgeting, cost controlling and reporting.


We help clients develop their partnering strategies and navigate the entire business development process, providing an end-to-end service that includes generating partnering leads, intelligence gathering, deal structuring, negotiations, and alliance management


We provide the full range of corporate development services from strategizing and contracting to human resourcing and operations

The Team

Anders Hinsby

Anders has more than 15 years of experience as a biotech executive and investor. He is a co-founder of Orphazyme A/S where he served as CEO from 2009 to 2019. In Orphazyme he led the formation of a late-development stage biopharmaceuticals company with a focus on rare and neurodegenerative diseases, as well as the IPO on NASDAQ in Copenhagen in 2017 raising 90 MUSD. Prior to Orphazyme, he was a Partner in a major Danish life science dedicated venture capital fund, BankInvest Biomedical Venture, where he also served as a Director in Boards including Santaris Pharma and F2G. Anders holds a M.Sc. in Human Biology and a Ph.D. in Medicine from the University of Copenhagen. +

Casper Tind Hansen

Casper has 15 years of expertise in pharma, biotech, and venture capital. He has taken on various roles in Marketing and Business Development at Lundbeck and Nycomed, he was part of the investment team at Novo Ventures, and has been CEO of Pcovery, a Danish Discovery stage biotech company. Casper is the co-founder of Orphazyme and Embark Biotech. He holds a M.Sc in Human Biology from the University of Copenhagen.

Ian Laquian

Ian has over 15 years of experience in building companies, franchises, portfolios and products. He has had senior roles with increasing responsibility within R&D, Business Development, and Marketing at Nycomed and Takeda; overseeing development of key assets in Alzheimer’s Disease, Schizophrenia and Depression. Ian holds a B.Sc. in Biochemistry from the University of Waterloo, and a M.Sc. in Biochemistry and MBA from the University of Ottawa.


Jakob Dynnes Hansen

More than 25 years of experience from biotech and financing. Previously, CFO of Evolva, a Swiss public biotech company, Nuevolution and Zealand Pharma, Senior member of Corporate Finance Team at Unibank (now Nordea), Head of Market Research at Novo Nordisk. MSc (Econ.,University of Copenhagen), MBA (INSEAD)+

John Haurum

Non-executive Director in various European biotech companies (Synklino Aps. (DK), Neophore Ltd. (UK), Storm Ltd. (UK), Agomab Therapeutics (Belgium), and Synact Pharma AB (Sweden) in addition to being an advisor to BiOrigin. Previously, he was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company, that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. Before, he was VP Research at ImClone Systems, New York (2010-2012) and Chief Scientific Officer and cofounder of Symphogen A/S, Denmark (2000-2009). After graduating in Medicine in Aarhus, Denmark (1992), Dr. Haurum received a D.Phil. in Immunology from University of Oxford, UK based on work done at the Institute of Molecular Medicine, John Radcliffe Hospital, Oxford. Subsequently, he took up positions as Associate Professor at the Danish Cancer Society and completed his medical training.+

Line Kromann Jørgensen

Line has more than 20 years of experience in financial management. She has a background as senior auditor at Deloitte followed by Finance Manager roles at Momondo A/S. In addition to her main focus on accounting and reporting, Line is well founded in general tax and VAT matters. At BiOrigin, she supports client management with budgeting, reporting and other financial management. Line holds a M.Sc. in Business Economics and Auditing from the Copenhagen Business School.+

Per Fischer

Dr. Fischer has 24 years experience from the biotech and pharmaceutical industry within product development and business development. He has experience from product and business development in big pharma, founded and run several biotech companies, and served a business and product development consultant within the sector. He holds a D.Phil. from University of Oxford and has 6 years of laboratory experience within immunology and infectious diseases. He currently serves as the CEO of MinervaX ApS, Helion Biotech ApS, and Fischer BioConsult ApS.+

Rita Balice-Gordon

Rita Balice-Gordon, Ph.D., is the Chief Scientific Officer of Muna Therapeutics, a newly formed biotech company focused on disease modifying therapies for neurodegenerative diseases and neuro-inflammation, with seed funding secured. She is also an Entrepreneur-in-Residence at Novo Seeds/Novo Holdings/BiOrigin, developing R&D and financial strategies for biotech startups. Prior to taking on these roles, Rita was the Global Head, Rare and Neurologic Diseases Research Therapeutic Area at Sanofi, Inc. for several years. She led groups of ~200 scientists based in Boston and Paris working on a portfolio of ca. 30 pre-clinical and early development stage projects using small molecules, antibodies and gene therapy as modalities for innovative and transformative therapeutics for patients with rare genetic disorders including lysosomal storage disorders, inborn errors of metabolism and renal and musculoskeletal diseases; Multiple Sclerosis; Parkinson’s Disease and other neurodegenerative diseases. Before joining Sanofi, she was Vice-President and Head of Circuits, Neurotransmitters and Signaling in Pfizer’s Neuroscience and Pain Research Unit, led the psychiatry and pain portfolios, including bringing several assets to Ph1-Ph2a, and was Head of the Worldwide Research and Development Postdoctoral Program at Pfizer. Rita has consulted on the creation of several NewCos, and partnered with business development colleagues to spin out several assets into NewCos. Prior to her career in biopharma, Rita was Professor of Neuroscience and Chair of the Neuroscience Graduate Group in the Perelman School of Medicine at the University of Pennsylvania, where she currently holds an appointment as Adjunct Professor. Rita and her laboratory have studied the cell-cell signaling mechanisms underlying synapse formation and maintenance, mechanisms underlying neuromuscular development and disease, and pathophysiologic mechanisms underlying autoimmune CNS disorders affecting cognition and behavior. She was continuously funded by the NIH for more than 30 years, authored more than 100 scientific papers, received several awards and honors, has given hundreds of invited research talks around the world, has chaired or served on many NIH, national and international committees, study sections, editorial boards and research organization and biotech scientific advisory boards. Rita is an elected Fellow of the American Association for the Advancement of Science.+

Board of Directors

Emmanuelle Coutanceau

Partner of Novo Seeds. Emmanuelle has more than 10 years of experience in venture capital investment. She sits on the board of directors of several European biotech companies, including IO Biotech, Inthera, Corwave, Antag Therapeutics and Minervax. Prior to joining Novo Seeds, Emmanuelle was Partner Life Sciences at Auriga Partners, where she was in charge of seed stage investments for Auriga IV Bioseeds, a seed fund dedicated to projects related to infectiology and microbiology. From 2007 until 2014, she was part of Omnes capital (formerly Crédit Agricole Private Equity) life sciences team with multiple portfolio companies leading to successful exits or IPOs. She was also in charge of the Seed Stage Investment Program and actively invested and sat on the board of directors of several companies in Belgium and The Netherlands.


Jeroen Bakker

Joined Novo Holdings in 2018 and is a Principal in the Novo Seeds team. Jeroen has a broad background comprising of life science consultancy, biotech and venture capital. Previously, Jeroen worked at M Ventures, the corporate investment group of Merck, focusing on early-stage investments in US, EU and Israel. Through his work in consultancy, Jeroen raised 10+ EUR million in funding for biotech and translational academic research. Jeroen worked in biotech at Syntaxin Ltd (acquired by Ipsen) and through his scientific training published several articles on innate immunity. He holds a PhD in immunology from the University of Amsterdam and has been a visiting fellow at the La Jolla Institute for Allergy and Immunology and University of Iowa.+